Reva Medical Receives CE Mark Approval of the Full Fantom Encore Product Line

REVA Medical, Inc. a leader in bioresorbable polymer technologies for vascular applications, today announced it has received CE Mark approval for its full Fantom® Encore product line. This covers Fantom Encore in the 3.0 and 3.5 mm diameters, expanding the approved product line beyond the 2.5 mm diameter scaffold, which has a market-leading strut profile of 95 microns.

Fantom Encore is REVA’s third-generation coronary bioresorbable scaffold. Commercialization of Fantom, a second-generation product line that previously received CE Mark approval, began in the second quarter of 2017 in Germany and has expanded to additional countries, including Switzerland, Austria, and Turkey. REVA is actively engaged in continuing its sales expansion in Europe, the Middle East and South America with distribution partners as previously announced.

“With this approval we have reached an important milestone in our commercial growth plan for our coronary scaffolds,” said Reggie Groves, REVA’s CEO. “In addition to pursuing distribution partnerships and increasing our clinical evidence to support marketing activities, we have extended our technological lead in this area. We are on track to launch the Fantom Encore product line later this year.”

Fantom Encore offers a thinner strut profile compared to Fantom without compromising strength or visibility under x-ray. Thinner strut profiles have been associated with improved outcomes and ease-of-use, which are critical for broader adoption of bioresorbable scaffold technology.

Like Fantom, Fantom Encore is made from Tyrocore™, REVA’s proprietary bioresorbable polymer. Fantom and Fantom Encore are second- and third-generation scaffolds, respectively, offering differentiated features compared to first-generation scaffolds such as Absorb, including thinner profiles, improved ease-of-use, and full x-ray visibility. These advantages are derived from Tyrocore, which is different from the polylactic acid polymer used to construct Absorb.

REVA recently reported positive two-year results with Fantom from the FANTOM II trial. These results included a low 5.0% rate of major adverse cardiac events (“MACE”) in 240 patients. MACE is a stringent definition of safety and efficacy combining all events related to cardiac death, myocardial infarction, and target lesion revascularization. The endpoint of target lesion failure (“TLF”) is similar to MACE but only includes myocardial infarction events that are related to the treated vessel. Following this definition, the two-year TLF rate from 240 patients in the FANTOM II trial was 4.6%. This compares favorably to two-year TLF rates for Absorb of 11.0% and Xience of 7.9% in the 2,008-patient ABSORB III trial.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s